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Letter to the Editor
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To the Editor,
Serology may offer valuable information during
COVID-19 pandemic; however, published papers mainly
reported the results of symptomatic patients having positive
RT-PCR on upper respiratory tract specimens [1]. More
studies are needed to address whether asymptomatic
patients, or patients with chest imaging compatible with
COVID-19 but negative RT-PCR, have different antibody
response that could influence assays performances. We
wanted to share our data from Turkey where 4,323,596
COVID-19 cases were detected out of 44,087,628 PCR tests
by April 20, 2021 but there are only a couple of published
studies about serodiagnosis of the infection.
According to the interim guidance of WHO (Diagnostic
testing for SARS-CoV-2), interpretations of serology should
be made by an expert and are dependent on several factors
including the timing of the disease, clinical morbidity, the
epidemiology and prevalence within the setting, the type
of test used, the validation method, and the reliability of
the results . IDSA (Infectious Diseases of South America)
guideline suggest not to use any serological test during the
first 2 weeks following infection and to use IgG antibody
to provide evidence of COVID-19 infection in symptomatic
patients with a high clinical suspicion and repeatedly
negative PCR results [2]. Commercially available serological
assays for SARS-CoV-2 like ELISAs and lateral flow assays
are high throughput, relatively inexpensive and use readily
available instrumentation. These assays are performed with
recombinant antigens, such as the spike protein (the main
surface glycoprotein that is used to attach and enter cells)
of SARS-CoV-2; the receptor-binding domain (RBD), which
is part of the spike protein; or the viral nucleoprotein and
can be handled at biosafety level 2. However neutralization
assays with replication-competent SARS-CoV-2 have to
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be performed in biosafety level 3 facilities, which limits
their application. IgM titer may be detectable 10 to 12 days
after the first manifestation of the symptoms and IgG is
measurable subsequently to IgM, after 12–14 days from the
infection [3]. The maximum viremia levels are measured
during the initial period of the disease. From the 10–14th
day forward, the concentration decreases as a consequence
of the immune response that justify the therapeutic use of
convalescence plasma at an early stage of severe COVID-19
[4]. Positive serology can suggest an early, active, or late
phase of the disease. After the 15th day, the sensitivity of
RT-PCR is 45, 5% and serological tests above 90% [5]. Due
to the high sensitivity of serological tests after the 10th
day from the onset of the disease, it is recommended to
utilize qualitative and quantitative anti-SARS-CoV2 IgM
and IgG detection in the advanced stage of the infection,
particularly, in patients with negative RT-PCR results [6].
The nature of the virus-specific IgA response against SARSCoV-2 infection in humans remains poorly understood. In
a recent study assessing the prevalence of IgG, IgA, and IgM
antibodies recognizing the SARS-CoV-2 from 132 infected
patients, neutralization was more closely correlated with
IgA than IgM or IgG in the first weeks after symptom onset
although this response was not associated with COVID-19
severity [7].
We have analyzed serum samples of 245 patients
among PCR positive patients (n: 154) who are eligible for
convalescent plasma donation and PCR negative patients
(n: 91) with high clinical and/or radiological suspicion of
COVID-19. Our study was approved by the ethics committee
of the Marmara University Training and Research Hospital
(approval number: 09.2020.740). Viral RNA was extracted
from nasopharyngeal swab samples by using Bio-speedy
viral nucleic acid buffer (Bioexen LTD, Turkey) and RT-PCR
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was performed with Bio-speedy COVID-19 qPCR detection
kit, Version 2 (Bioexen LTD) using primers and probes
targeting the RNA-dependent RNA polymerase (RdRp) gene
fragment in a LightCycler 96 System (Roche, Switzerland).
The Weimi Diagnostic COVID-19 IgG cassette lateral flow
assay was performed with 10 μL of serum/plasma and the
result was read at 10 min visually. Serum samples were kept
in –20 ºC until antibody assays were available. The Abbott
SARS-CoV-2 ELISA assay was performed on an i2000
Abbott Architect (Abbott Diagnostics, USA) for detecting
IgG antibodies against the viral nucleocapsid protein. The
Euroimmun SARS-CoV-2 ELISA assay was performed
on a Euroimmun Analyser I (Euroimmun Diagnostics,
Germany) for detecting anti-SARS-CoV-2 IgG and IgA
directed against the S1 domain of viral spike protein. Percent
agreement of ELISA tests was calculated using Cohen’s
Kappa test. Chest CT exams were performed within 1–3
days of PCR assay. Image analysis was performed using
PACS (Picture Archiving and Communication System)
workstation (INFINITT Healthcare Co., Ltd).
The median age (IQR) was 43(35–52.5) for PCR positive
patients (70.6% of them were male) and 51(38–68.2) for
PCR negative patients (47.8% of them were male). For
PCR positive patients, Abbott IgG was positive in 92,9%
, Euroimmune IgG was positive in 91.6%, Euroimmune
IgA was positive in 91.6%, Weimi Diagnostic Lateral flow
assay was positive in 86.6% whereas positivity was detected
for the given methods in 39.6%, 39.6%, 43.9% and 40.6%
in PCR negative patients. The highest positivity rate was
detected in samples taken 21–29 days after the PCR request
(Table). There was a linear increase of Kappa values (percent
agreement between assays) which was 0.56, 0.79 and 0.88
between Abbott IgG and Euroimmun IgG tests and 0.48,
0.54 and 0.57 between Abbott IgG and Euroimmun IgA tests
for samples have been taken 14–20 days, 21–29 days and ≥30
days, respectively for PCR positive patients. Kappa values
were 1 between Abbott IgG and Euroimmun IgG tests and
0.80, 0.90. and 1 between Abbott IgG and Euroimmun IgA

tests for samples have been taken 14–20 days, 21–29 days
and ≥30 days, respectively for PCR negative patients. In
91 patients PCR was negative despite there were COVID-19
related changes in chest CT and 77% of them were treated
empirically. When antibody tests are available positivity was
detected in about 40% of the samples that might support the
diagnosis.
Mei et al. [8] compared the utility of Roche, Abbott,
and Euroimmun SARS-CoV-2 assays for correlation with
neutralizing antibodies and a modest correlation, but poor
concordance was reported for all assays. Authors suggested
that patients infected with SARS-CoV-2 develop a broadbased antibody repertoire against multiple proteins and
epitopes, but only some of these antibodies have neutralizing
properties. Patients who were intubated, had cardiac injury,
or acute kidney injury from COVID-19 infection had higher
neutralizing titers relative to those with mild symptoms. In a
meta review, 57 publications reporting on a total of 54 study
cohorts with 15,976 samples, of which 8526 were from cases
of SARS-CoV-2 infection were evaluated [9]. The sensitivity
of antibody tests is too low in the first week since symptom
onset to have a primary role for the diagnosis of COVID-19,
but they may still have a role complementing other testing in
individuals presenting later, when RT-PCR tests are negative,
or are not done. Beavis et al. [10] have studied 86 samples
from SARS-CoV-2 PCR-negative patients, and 82 samples
from SARS-CoV-2 PCR-positive patients, and reported that
Euroimmun Anti-SARS-CoV-2 ELISA assay demonstrated
good sensitivity for detection of IgA and excellent sensitivity
for detection of IgG antibodies from samples collected ≥4
days, good specificity for IgA and excellent specificity for
IgG.
Limiting factors of our study that single serum samples
for each patients were tested and since consecutive samples
are not available we have no information about the duration
of the seropositivity. Moreover, there is a debate on the
possibility of waning immunity, and research on kinetics of
antibody responses to SARS-CoV-2 is therefore needed to

Table. Antibody positivity according to the days between PCR and serology tests.
PCR positive patients
14–20 days
(n = 45)

21–29 days
(n = 47)

>=30 days
(n = 62)

0–20
(n = 58)

21–29 days
(n = 23)

>=30 days
(n = 10)

Euroimmun IgG,
positive, n (%)

38 (84.4)

45 (95.7)

58 (93.5)

15 (25.9)

16(69.6)

5(50.0)

Abbott IgG,
positive, n (%)

42 (93.3)

44 (93.6)

57 (91.9)

15(25.9)

16(69.6)

5(50.0)

Euroimmun IgA,
positive, n (%)

41 (91.1)

46 (97.9)

54 (87.1)

20(34.5)

15(65.2)

5(50.0)

ELISA Test

2796

PCR negative patients

KARAHASAN et al. / Turk J Med Sci
assess added value of serology in diagnosing COVID-19 in
the future [11].
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